LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

Kodu・Aktsiate loetelu・Novo Nordisk A-S

Novo Nordisk A-S

Suletud

Sektor Tervishoid

112.01 -0.39

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

111.12

Max

113.16

Põhinäitajad
By Trading Economics
Sissetulek	-5.4B 20B
Müük	2.7B 68B
P/E Sektori keskmine	49.94 112.16
Aktsiakasum	4.49
Kasumimarginaal	29.459
EBITDA	-1.2B 36B

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+37.28 upside

Turustatistika
By TradingEconomics
Turukapital	2.4B 396B
Eelmine avamishind	112.4
Eelmine sulgemishind	112.01

Uudiste sentiment

By Acuity

45%

55%

169 / 389 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

N/A / 117.81 Toetus ja vastupanu

Novo Nordisk A-S Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. sept 2024, 19:26 UTC

Suurimad hinnamuutused turgudel

Skye Bioscience Shares Gain After Highlighting Safety of In-Development Obesity Treatment

26. okt 2024, 11:00 UTC

Peamised uudised

Heard on the Street: Pfizer's Activist Battle Might Fizzle -- but Its Stock Probably Won't -- WSJ

25. okt 2024, 09:30 UTC

Peamised uudised

Big Food Is Learning to Love Weight-Loss Drugs -- Heard on the Street -- WSJ

4. okt 2024, 12:01 UTC

Peamised uudised

As Weight-Loss Drugs Battle, Upstart Viking -2-

4. okt 2024, 12:01 UTC

Peamised uudised

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer -- IBD

3. okt 2024, 14:45 UTC

Peamised uudised

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3. okt 2024, 13:12 UTC

Peamised uudised

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3. okt 2024, 12:51 UTC

Market Talk

Novo Nordisk's Weight-Loss Jab Trial Will Be Defining -- Market Talk

2. okt 2024, 13:48 UTC

Tulu

Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com

2. okt 2024, 12:28 UTC

Market Talk

Novo Nordisk Shares Unlikely to Move Ahead of New Drug Data -- Market Talk

2. okt 2024, 09:00 UTC

Market Talk

Novo Nordisk's New Weight-Loss Jab Could Support Co Into 2030s -- Market Talk

26. sept 2024, 13:15 UTC

Market Talk

Novo Nordisk's Share Price Looks Capped Ahead of New Drug Data -- Market Talk

26. sept 2024, 11:51 UTC

Market Talk

Novo Nordisk Senate Hearing Removes a Share Overhang -- Market Talk

23. sept 2024, 10:37 UTC

Peamised uudised

Fed Uncertainty Is History. Now Markets Need to Brace for Election Volatility. -- Barrons.com

23. sept 2024, 10:37 UTC

Peamised uudised

Fed Uncertainty Is History. Now Markets Need to -2-

20. sept 2024, 16:30 UTC

Market Talk

'Knee-Jerk' Corbus Selloff Seen as Buying Opportunity -- Market Talk

20. sept 2024, 13:55 UTC

Peamised uudised

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

20. sept 2024, 12:46 UTC

Peamised uudised

Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

20. sept 2024, 09:30 UTC

Peamised uudised

The Price War in Weight-Loss Drugs Is Here -- WSJ

12. sept 2024, 13:00 UTC

Peamised uudised

Senators Target Influencers, Telehealth Firms for Misleading Weight-Loss and Other Drug Promotion -- WSJ

12. sept 2024, 11:45 UTC

Market Talk

Tulu

Novo Nordisk's Obesity Pill Data Confirm Investor Optimism -- Market Talk

12. sept 2024, 10:30 UTC

Market Talk

Tulu

Novo Nordisk's Amycretin Obesity Pill Slightly Disappoints on Safety -- Market Talk

11. sept 2024, 12:08 UTC

Peamised uudised

Novo Nordisk Stock Rises After Study Finds Obesity Drug Safe For Kids -- Barrons.com

9. sept 2024, 07:56 UTC

Market Talk

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

3. sept 2024, 11:09 UTC

Peamised uudised

Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly. -- Barrons.com

27. aug 2024, 05:30 UTC

Peamised uudised

Weight-Loss Drugs Get More Good News. For Investors, It's Still Too Soon to Celebrate. -- Barrons.com

14. aug 2024, 12:01 UTC

Market Talk

Tulu

Novo Nordisk's Pricing and Pipeline to Remain Hot Topics -- Market Talk

9. aug 2024, 11:30 UTC

Peamised uudised

Eli Lilly Is Gaining on Novo Nordisk in the Obesity Race -- Heard on the Street -- WSJ

9. aug 2024, 07:30 UTC

Market Talk

Novo Nordisk Share Pullback Represents Great Opportunity -- Market Talk

8. aug 2024, 15:44 UTC

Peamised uudised

Tulu

Eli Lilly Shows We Haven't Hit Peak Obesity Yet -- WSJ

Võrdlus sarnastega

Hinnamuutus

Novo Nordisk A-S Prognoos

Hinnasiht

By TipRanks

37.28% tõus

12 kuu keskmine prognoos

Keskmine 154.25 USD 37.28%

Kõrge 160 USD

Madal 146 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Novo Nordisk A-S 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Novo Nordisk A-S aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 117.81Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

169 / 389 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Novo Nordisk A-S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.